Detalhe da pesquisa
1.
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Ann Hematol
; 101(4): 755-762, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083525
2.
Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
Isr Med Assoc J
; 24(10): 629-633, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309856
3.
[PROLONGED POST-COVID-19 ANEMIA].
Harefuah
; 161(12): 732-735, 2022 Dec.
Artigo
em Hebraico
| MEDLINE | ID: mdl-36916110
4.
Multiple Myeloma with Systemic Amyloidosis: Serum Free Light Chain Dimerization Analysis in the Diagnosis of an Equivocal Case of Plasma Cell Dyscrasia.
Isr Med Assoc J
; 23(7): 459-461, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251134
5.
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab.
J Microbiol Immunol Infect
; 57(1): 189-194, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37805361
6.
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
Cancer Med
; 13(3): e6997, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400683
7.
Lymphoproliferative disease detected by breast cancer screening.
J Med Screen
; 29(4): 255-259, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35818749
8.
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Leuk Lymphoma
; 62(1): 118-124, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32981410